Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Zafgen Inc    ZFGN

ZAFGEN INC

(ZFGN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2018 Financial Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/06/2019 | 06:01pm EDT

BOSTON, March 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a conference call on Monday, March 11, 2019 at 5:00 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2018.

Participants may access the call by dialing (844) 824-7428 in the U.S. or (973) 500-2177 outside the U.S. and referencing conference ID number 2067548. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations. A replay of this conference call will be available beginning at 8:00 p.m. ET on March 11, 2019 through March 18, 2019 by dialing (855) 859-2056 in the U.S. or (404) 537-3406 outside the U.S. To access the replay please provide conference ID number 2067548.

About Zafgen

Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders and is currently advancing programs for type 2 diabetes, Prader-Willi syndrome and liver diseases. Learn more at www.zafgen.com.

Media/Investor Relations Contacts:
Zafgen, Inc.
Patricia Allen
Chief Financial Officer
617-648-9792

Media
Krystle Gibbs
Ten Bridge Communications 
krystle@tenbridgecommunications.com
508-479-6358

Investors
John Woolford
Westwicke
john.woolford@westwicke.com
443-213-0506

zag logo.png


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZAFGEN INC
04/04ZAFGEN, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/04Zafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
03/27GLANCY PRONGAY & MURRAY LLP : Announces Investigation on Behalf of Zafgen, Inc. ..
BU
03/15Law Offices of Howard G. Smith Announces Investigation on Behalf of Zafgen, I..
BU
03/14ZAFGEN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
03/13Zafgen to Present at the 31st Annual ROTH Conference
GL
03/11ZAFGEN : 4Q Earnings Snapshot
AQ
03/11Zafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Resu..
GL
03/07ZAFGEN : to Present at the Cowen and Company 39th Annual Health Care Conference
AQ
03/07ZAFGEN : to Host to Discuss Fourth Quarter and Full Year 2018 Financial Results
AQ
More news
Financials ($)
Sales 2019 2,00 M
EBIT 2019 -62,6 M
Net income 2019 -65,7 M
Finance 2019 94,0 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 1,34x
EV / Sales 2020 22,8x
Capitalization 96,6 M
Chart ZAFGEN INC
Duration : Period :
Zafgen Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZAFGEN INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 6,00 $
Spread / Average Target 132%
EPS Revisions
Managers
NameTitle
Jeffrey S. Hatfield Chief Executive Officer & Director
Peter Barrett Chairman
Patricia L. Allen CFO & Principal Accounting Officer
Dennis D. Kim Chief Medical Officer
John L. LaMattina Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ZAFGEN INC-49.29%97
GILEAD SCIENCES-1.09%80 255
VERTEX PHARMACEUTICALS1.70%42 991
REGENERON PHARMACEUTICALS-10.57%35 789
GENMAB5.11%10 423
SAREPTA THERAPEUTICS INC4.27%8 594